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Abstract
Objectives: DISHEVELLED,	 EGL-10,	 PLECKSTRIN	 (DEP)	 domain-containing	 1B	
(DEPDC1B)	 promotes	 dismantling	 of	 focal	 adhesions	 and	 coordinates	 detachment	
events	during	cell	cycle	progression.	DEPDC1B	is	overexpressed	in	several	cancers	
with	expression	inversely	correlated	with	patient	survival.	Here,	we	analysed	the	role	
of	DEPDC1B	in	the	regulation	of	murine	and	human	skeletal	myogenesis.
Materials and methods: Expression	dynamics	of	DEPDC1B	were	examined	 in	mu-
rine and human myoblasts and rhabdomyosarcoma cells in vitro by RT-qPCR and/
or	immunolabelling.	DEPDC1B	function	was	mainly	tested	via	siRNA-mediated	gene	
knockdown.
Results: DEPDC1B	 was	 expressed	 in	 proliferating	 murine	 and	 human	 myoblasts,	
with	expression	then	decreasing	markedly	during	myogenic	differentiation.	SiRNA-
mediated	knockdown	of	DEPDC1B	reduced	myoblast	proliferation	and	induced	entry	
into	myogenic	differentiation,	with	deregulation	of	key	cell	cycle	regulators	(cyclins,	
CDK,	CDKi).	DEPDC1B	and	β-catenin co-knockdown was unable to rescue prolifera-
tion	 in	myoblasts,	suggesting	that	DEPDC1B	functions	 independently	of	canonical	
WNT	signalling	during	myogenesis.	DEPDC1B	can	also	 suppress	RHOA	activity	 in	
some	cell	 types,	but	DEPDC1B	and	RHOA	co-knockdown	actually	had	an	additive	
effect by both further reducing proliferation and enhancing myogenic differentiation. 
DEPDC1B	was	expressed	in	human	Rh30	rhabdomyosarcoma	cells,	where	DEPDC1B 
or	RHOA	 knockdown	promoted	myogenic	 differentiation,	 but	without	 influencing	
proliferation.
Conclusion: DEPDC1B	plays	a	central	role	in	myoblasts	by	driving	proliferation	and	
preventing precocious myogenic differentiation during skeletal myogenesis in both 
mouse and human.
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1  | INTRODUCTION
DISHEVELLED,	 EGL-10,	 PLECKSTRIN	 (DEP)	 domain-containing	 1B	
(DEPDC1B)	and	 its	paralog	DEPDC1A	are	cell	cycle–regulating	pro-
teins.1 The DEPDC1B	gene,	at	human	chromosome	5q12,	encodes	a	
61	kDa	protein	of	529	amino	acids.	DEPDC1B	contains	an	N-terminal	
DEP	 domain	 and	 a	 C-terminal	 RHO-GAP	 (GTPase-activating	 pro-
tein)-like	domain.	The	DEP	domain	is	a	globular	region	discovered	in	
DISHEVELLED,	EGL-10	and	PLECKSTRIN	and	plays	a	role	in	mediat-
ing	membrane	localization,2	and	DEPDC1B	is	usually	membrane-asso-
ciated,	being	highly	expressed	during	G2/M	phase	of	the	cell	cycle.1,3 
The	RHO-GAP	domain	is	involved	in	RHO	GTPase	signalling	(eg	RAC,	
CDC42	and	RHO)	that	regulates	cell	motility,	growth,	differentiation,	
cytoskeleton	 reorganization	 and	 cell	 cycle	 progression.4 Membrane 
association	via	the	DEP	domain	enables	DEPDC1B	to	interact	with	G	
protein-coupled	receptors,	as	well	as	membrane	phospholipids	neces-
sary	for	Wnt	signalling.	However,	the	GAP	domain	of	DEPDC1B	lacks	
the	critical	arginine	residue	required	for	GAP	activity.1	The	GAP	do-
main	of	DEPDC1B	can	also	interact	with	the	nucleotide-bound	forms	
of	RAC1	and	can	control	their	activation.5,6
DEPDC1B	 can	 also	 indirectly	 suppress	 activation	 of	 RHOA.1 
The	transmembrane	protein	tyrosine	phosphatase	receptor	type	F	
(PTPRF)	and	 the	guanine	nucleotide	exchange	 factor	H1	 (GEF-H1)	
are	required	for	RHOA	activation.	DEPDC1B	inactivates	RHOA	by	
competing	 for	binding	of	PTPRF,	 so	 allowing	 cell	 de-adhesion	and	
cell cycle progression.1
DEPDC1B	expression	oscillates	during	cell	cycle	progression,	ac-
cumulating	at	the	G2	phase,	similar	to	checkpoint	proteins	such	as	cy-
clin	B,	which	correlates	with	its	function	as	a	regulator	of	cell	cycle.1 
DEPDC1B	knockdown	induces	a	significant	delay	in	transition	to	mito-
sis,	due	to	impairment	of	the	de-adhesion	process.1	RHOA	is	required	
for	 formation	and	 integrity	of	 focal	adhesion	points,	and	DEPDC1B,	
as	an	indirect	inhibitor	of	RHOA,	promotes	dismantling	of	focal	adhe-
sions,	necessary	for	morphological	changes	preceding	mitosis.
RHO	GTPases	including	RHOA,	RAC1	and	CDC42	are	also	crucial	
regulators	of	skeletal	myogenesis,7 and their precise temporal regula-
tion is critical for efficient myotube formation.7,8	RHOA	is	required	for	
the initial induction of myogenesis by activating serum response factor 
(SRF)	9 which induces the myogenic transcription factor MyoD.10-12 In 
myocytes	however,	RHOA	perturbs	localization	of	M-cadherin,	a	cell	
adhesion	molecule	required	for	myoblast	fusion,13 and so needs to be 
inactivated before myoblast fusion.14	Such	inactivation	is	mediated	by	
RHOE	and	GRAF1.15,16	Therefore,	precise	modulation	of	RHOA	activ-
ity is required for differentiation to proceed.17 While Rac1 and CdC42 
are	required	for	myoblast	fusion	in	Drosophila	 in	vivo,18	overexpres-
sion	of	RAC1	or	CDC42	inhibits	myogenesis	in	rat	myoblasts.19	RAC1	
and	CDC42	can	have	this	dual	role	by	activating	the	C-Jun	N-terminal	
kinase	 (JNK),	a	negative	regulator	of	myogenesis,	but	also	activating	
the	stress-activated	protein	kinase	(SAPK)	and	p38:	pathways	neces-
sary for myogenesis.20	Moreover,	RAC1	inhibits	myogenic	differenti-
ation by preventing complete withdrawal of myoblasts from the cell 
cycle 21	 and	 exogenous	 expression	 of	RAC1	 and	CDC42	 impair	 cell	
cycle	exit	and	induce	loss	of	cell	contact	inhibition.22 This suggests a 
function	of	RAC1	and	CDC42	during	proliferation,	rather	than	during	
the differentiation process.
DEPDC1B	expression	is	repressed	by	PITX2,	a	bicoid-related	ho-
meobox	 transcription	 factor	 implicated	 in	 regulating	 the	 left-right	
patterning and organogenesis.6,23,24 The first intron of the human and 
mouse DEPDC1B	gene	contains	multiple	consensus	DNA-binding	sites	
for	PITX2,	and	knockdown	of	PITX2	in	murine	C2C12	myoblasts	pro-
motes	an	increase	in	DEPDC1b	at	the	protein	level.	PITX2	particularly,	
but	also	PITX3,	are	additionally	involved	in	regulation	of	muscle	devel-
opment	and	adult	muscle	stem	(satellite)	cell	function.25-31
Finally,	 DEPDC1B	 is	 overexpressed	 in	 various	 cancers	 includ-
ing	 breast,	 oral,	 non-small-cell	 lung,	 melanoma	 and	 prostate,	 and	
represents a potential biomarker and therapeutic target.3,5,32-36 
Interestingly,	in	many	human	cancer	cells,	DEPDC1B	also	has	a	nu-
clear location.37	 DEPDC1B	 overexpression	 in	 breast	 cancer	 cells	
can	increase	phosphorylation	of	ERK	and	promote	cell	proliferation	
and delay cell death.3	DEPDC1B	is	also	highly	expressed	in	oral	can-
cer	 and	 overexpression	 induces	 augmentation	 of	 ERK1/2	 activity	
by	RAC1	GTP,	promoting	cell	migration	and	 invasion	 in	cancer	cell	
lines.5	 DEPDC1B	 up-regulation	 in	 non-small-cell	 lung	 cancer	 has	
a	 reverse	 correlation	with	 patient	 survival,	 and	 its	 overexpression	
promotes tumour cell migration and invasion through activating 
Wnt/β-catenin signalling.33	Increased	DEPDC1B	expression	in	pros-
tate cancer is associated with an advanced clinical stage of disease.32 
Deregulation	 of	 RHO	GTPases	 is	 implicated	 in	 tumours	 that	 have	
characteristics	of	 skeletal	muscle	 (rhabdomyosarcomas),22,38,39 but 
the	role	of	DEPDC1B	in	rhabdomyosarcomas	is	unknown.
Here,	 we	 examined	 the	 role	 of	 DEPDC1B	 in	 both	 mouse	 and	
human skeletal myogenesis. DEPDC1B	was	expressed	in	both	mouse	
and	human	proliferating	myoblasts,	but	expression	fell	precipitously	
during	 myogenic	 differentiation.	 SiRNA-mediated	 knockdown	 of	
DEPDC1B	 drastically	 reduced	 proliferation	 and	 induced	 preco-
cious	 myogenic	 differentiation	 in	 both	 species.	 In	 myogenic	 cells,	
DEPDC1B	 function	 was	 unaffected	 by	 manipulation	 of	 β-catenin,	
while	DEPDC1B	 expression	was	 unaltered	 by	 PITX2	 levels.	Given	
that	DEPDC1B	 can	 suppress	RHOA	activation,	 it	was	 unexpected	
that	 DEPDC1B/RHOA	 co-knockdown	 had	 an	 additive	 effect	 in	
myoblasts,	 reducing	 proliferation	 and	 enhancing	 differentiation	
more	than	DEPDC1B	knockdown	alone.	DEPDC1B	was	expressed	in	
human Rh30 rhabdomyosarcoma cells at a higher level than in myo-
blasts,	and	while	DEPDC1B down-regulation did not affect prolifera-
tion,	it	did	promote	myogenic	differentiation.	Thus,	DEPDC1B	plays	
a central role in driving proliferation and preventing differentiation 
during skeletal myogenesis.
2  | MATERIALS AND METHODS
2.1 | Ethics statement
Mice were bred in accordance with British law under the provisions 
of	the	Animals	(Scientific	Procedures)	Act	1986,	as	approved	by	the	
King's	College	London	Ethical	Review	Process	committee.
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2.2 | Myofibre isolation and culture of mouse 
satellite cells
Mice	aged	between	8	and	12	weeks	were	killed	by	cervical	disloca-
tion,	and	the	extensor	digitorum	longus	(EDL)	muscles	were	isolated	
and digested as previously described.40	 Freshly	 isolated	 myofibres	
were either cultured under non-adherent conditions or plated on 
Matrigel,	 and	 satellite	 cell-derived	 myoblasts	 were	 then	 expanded	
using	 DMEM-GlutaMAX	 (Invitrogen	 Life	 Technologies),	 with	 30%	
foetal	 bovine	 serum	 (FBS)	 (Gibco),	 10%	 horse	 serum	 (Invitrogen	
Life	Technologies),	 1%	 chick	 embryo	 extract	 (MP),	 10	 ng/mL	 bFGF	
(PreproTech)	and	1%	penicillin/streptomycin	 (Sigma),	again	as	previ-
ously described.40
2.3 | Cell culture
Immortalized	 human	 myoblasts	 (C25Cl48)	 were	 originally	 iso-
lated from the semitendinosus of a 25-year-old individual and 
were	 kindly	 provided	 by	 Dr	 Vincent	Mouly	 (Institute	Myology,	
Paris,	 France).41	 For	 proliferation,	 C25Cl48	 myoblasts	 were	
maintained	 in	 skeletal	 muscle	 cell	 growth	 medium	 (PromoCell,	
C-23160)	supplemented	with	20%	FBS,	or	switched	to	differenti-
ation	medium	(PromoCell:	C23161).	Proliferation	and	differentia-
tion	medium	were	supplemented	with	50	µg/mL	of	gentamycin.	
Preparation	 of	 cDNA	 from	 human	 primary	 myoblasts	 was	 de-
scribed previously.42
Rhabdomyosarcoma Rh3043	and	RMS-YM	cells	were	maintained	
in	 proliferation	 in	 DMEM-GlutaMAX	 (Invitrogen	 Life	 Technologies)	
with	 10%	 FBS	 (Gibco)	 and	 1%	 penicillin-streptomycin	 (Sigma).	 To	
induce	 differentiation,	 cells	 were	 cultured	 in	 growth	 medium	 until	
confluent	and	 then	switched	 to	differentiation	medium	 (PromoCell:	
C23161).
2.4 | Retroviral expression vectors
The	 retroviral	 backbone	 pMSCV-puro	 (Clontech)	 was	 modified	 to	
replace the puromycin selection gene with an IRES-eGFP to create 
pMSCV-IRES-eGFP,	 which	 served	 as	 control.44 Mouse Depdc1b-V5 
(Depdc1b-201	 transcript	 encoding	 for	 a	 protein	 of	 529	 amino	 acids	
with	 a	 V5-Polyhistidine	 region	 at	 the	 C-terminus)	 and	 the	 human	
PITX2C	cDNA	(transcript	variant	3,	coding	for	a	protein	of	324	amino	
acids)	were	 amplified	 by	 RT-PCR	 and	 cloned	 into	 pMSCV-IRES-eGFP. 
Retrovirus	was	then	packaged	in	293T	or	Phoenix	cells	using	standard	
methods.	Proliferating	satellite	cells	and	immortalized	human	myoblasts	
(C25Cl48)	were	transduced	 in	6-well	plates	with	500	μL	of	retrovirus	
or	 lentivirus	 in	1.5	mL	of	proliferation	medium	with	polybrene	 (4	μg/
mL).	Due	to	a	low	retroviral	transduction	rate	in	C25Cl48	immortalized	
human	myoblasts,	cells	were	expanded	and	GFP-positive	cells	 (trans-
duced	cells)	FAC-sorted,	expanded	for	a	few	days	and	then	stably	trans-
duced cells analysed.
2.5 | siRNA-mediated gene knockdown
Primary	satellite	cell-derived	myoblasts	were	transfected	with	siRNA,	
either	 Silencer	 Select	 Pre-designed	 siRNA	 used	 at	 8	 nM	 final	 con-
centration	 with	 Silencer	 Select	 Negative	 Control,	 or	 2	 nM	 Qiagen	
FlexiTube	 GeneSolution	 siRNA	 (eg	 GS218581	 for	 Depdc1b,	 four	
siRNAs:	 SI00977984,	 SI00977977,	 SI00977970,	 SI00977963).	 For	
immortalized	human	myoblasts	 (C25Cl48),	 siRNAs	were	 from	either	
Life	Technologies	 or	QIAGEN	 (FlexiTube	GeneSolution,	 four	 siRNAs	
used	 individually	at	2	nM	final	 concentration	with	AllStars	Negative	
Control).	All	siRNAs	are	detailed	in	Table	S1.
Satellite	cells	were	transfected	with	siRNA	in	DMEM-GlutaMAX,	
30%	FBS,	 10%	horse	 serum	 and	1%	 chick	 embryo	 extract	 for	 24	 h	
at	 37°C.	 Transfection	 of	 siRNA	 into	 immortalized	 human	myoblasts	
(C25Cl48)	 was	 performed	 in	 skeletal	 muscle	 cell	 growth	 medium	
(PromoCell)	for	24	h	at	37°C.	All	siRNA	transfections	were	performed	
using	Lipofectamine	RNAiMAX	as	per	manufacturer's	instructions.
2.6 | Western blot
Primary	 murine	 satellite	 cells	 were	 transfected	 with	 siRNA	 against	
DEPDC1B	(Si	Depdc1B	Mix	or	Si	Depdc1B	N2)	and	allowed	to	prolifer-
ate for 72 h and then collected for Western blot analysis. Blots were 
probed	against	DEPDC1B	(Sigma,	HPA072558-100UL,	1:500),	and	total	
protein	was	visualized	using	the	Bio-Rad	TGX	Stain-Free	Technology.	
For	quantification,	pixel	intensity	of	either	the	whole	lane	(total	protein	
image)	or	the	band	corresponding	to	DEPDC1B	(DEPDC1B	immunola-
belled	image)	was	quantified	using	Fiji,	and	knockdown	efficiency	pre-
sented	as	DEPDC1B	intensity	normalized	to	whole	protein	intensity.
2.7 | RT-qPCR
Mouse	or	human	myoblasts	were	cultured	in	6-well	plates	in	prolifera-
tion medium or switched to differentiation medium for the stated dura-
tion.	Total	RNA	was	extracted	using	the	RNeasy	Kit	(Qiagen)	and	cDNA	
prepared from 500 ng to 1 μg	 of	 RNA	with	 the	QuantiTect	 Reverse	
Transcription	Kit	with	genomic	DNA	wipeout	(QIAGEN).	qPCR	was	per-
formed	on	a	Mx3005PQPCR	system	(Stratagene)	with	Brilliant	II	SYBR	
Green	 reagents	 and	 ROX	 reference	 dye	 (Stratagene)	 or	 QuantiNova	
SYBR	 Green	 PCR	 Kit	 (QIAGEN)	 using	 primers	 shown	 in	 Table	 S2.	
Relative	expression	between	proliferating	and	differentiated	myoblasts	
and between control and test samples was measured in 3 replicates and 
significance	tested	using	a	two-tailed	Student's	t	test	in	Microsoft	Excel.
2.8 | Immunolabelling of cells
EdU	incorporation	was	assayed	using	a	Click-iT	EdU	Imaging	Kit	(Life	
Technologies)	as	per	manufacturer's	instructions.	Satellite	cell-derived	
myoblasts were immunolabelled as previously described.45	 Briefly,	
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fixed	myoblasts	were	permeabilized	with	0.5%	Triton	X-100/PBS	for	
10	min	at	 room	 temperature	and	blocked	with	5%	goat	 serum/PBS	
for	60	min	at	room	temperature.	Primary	antibodies	 (Table	S3)	were	
applied	overnight	at	4°C,	washed	and	visualized	with	fluorochrome-
conjugated	 secondary	 antibodies	 (Invitrogen)	used	at	1/500	 for	1	h	
at	 room	 temperature.	 Preparations	 were	 then	 incubated	 in	 DAPI	
(300	µM)	for	10	min	and	washed	in	PBS.
2.9 | Image acquisition
Images	of	plated	myoblasts	were	acquired	on	a	Zeiss	Axiovert	200	M	
microscope	using	a	Zeiss	AxioCam	HRm	and	AxioVision	software	ver-
sion	4.4	(Zeiss).	For	colocalization	analysis,	images	were	acquired	on	a	
confocal	microscope	(Zeiss).	Images	were	adjusted	globally	for	bright-
ness	and	contrast	and	analysed	with	ImageJ	and	RStudio46 software.
2.10 | Statistical testing
For	 analysis	 of	 immunolabelling	 following	 siRNA	 treatment,	 cells	 in	
multiple	unit	areas	per	well	per	experimental	condition	were	counted,	
and	data	from	each	mouse	were	expressed	as	a	single	mean	±	SD.	Such	
mean	±	SD	from	at	least	three	mice	were	used	for	each	condition	tested.	
Significant	difference	(P	<	.05)	between	control	and	a	test	sample	was	
determined	 using	 a	 paired	 two-tailed	 t	 test	 in	 Excel	 (Microsoft).	 For	
clonal	cell	 lines,	cells	 in	multiple	unit	areas	per	well	per	experimental	
condition	were	counted	and	data	 from	each	well	expressed	as	a	 sin-
gle	mean	±	SD.	Such	mean	±	SD	from	at	least	three	independent	wells	
were	used	for	each	condition	tested	and	significant	difference	(P	<	.05)	
between control and a test sample determined using an unpaired two-
tailed t	test	in	Excel	(Microsoft).	For	RT-qPCR,	at	least	three	indepen-
dently	siRNA-transfected	wells	per	condition	were	assessed.
3  | RESULTS
3.1 | DEPDC1B is located in the nucleus of murine 
satellite cell-derived myoblasts
Endogenous	DEPDC1B	protein	was	investigated	in	mouse	primary	
satellite	 cells	 using	 a	 commercially	 available	DEPDC1B	 antibody	
(HPA038255).	DEPDC1B	was	clearly	located	in	the	nuclei	of	pro-
liferating	satellite	cell-derived	myoblasts	ex	vivo	(Figure	1A).	After	
2	days	in	differentiation	medium,	DEPDC1B	remained	in	the	nuclei	
of	multinucleated	myotubes	and	unfused	cells	 (Figure	1B).	Using	
isolated	 myofibres	 that	 retain	 satellite	 cells	 in	 their	 niche,	 we	
found	 that	DEDPDC1B	was	not	detectable	 in	quiescent	 satellite	
cells,	but	was	present	at	low	levels	in	the	nuclei	of	activated	satel-
lite	cells	after	24	h	(Figure	S1A,B).	After	48	h	ex	vivo,	DEPDC1B	
was	 robustly	 expressed	 in	 the	 nuclei	 of	 myogenin-positive	 and	
myogenin-negative	 satellite	 cells	 (Figure	 S1C).	 Immunolabelling	
for	DEPDC1B	in	the	nuclei	of	satellite	cells	was	weaker	after	72	h	
in	culture	(Figure	S1D).
The	 expression	 profile	 of	 Depdc1b was assessed using RT-
qPCR. Depdc1b	was	expressed	in	proliferating	satellite	cell-derived	
myoblasts,	 but	 expression	 decreased	 rapidly	 during	 myogenic	
differentiation into myocytes and myotubes assayed at day 1 or 
2	of	differentiation:	 an	expression	profile	mirroring	 that	of	Pax7 
(Figure	1C).
DEPDC1B	localization	was	also	examined	in	mouse	primary	sat-
ellite	 cell-derived	 myoblasts	 using	 a	 mouse	 DEPDC1B-V5-tagged	
construct.	 Satellite	 cells	 were	 transduced	 with	 a	 Depdc1b-V5-
encoding retrovirus with an IRES-eGFP	(to	identify	transduced	cells)	
and	examined	during	proliferation	as	myoblasts	(Figure	S2A)	or	after	
1	 day	 of	 differentiation	 as	 myocytes	 and	 myotubes	 (Figure	 S2B)	
by	co-immunolabelling	 for	V5	 (DEPDC1B-V5)	and	GFP.	Exogenous	
DEPDC1B-V5	was	 localized	at	 the	cell	periphery	and	especially	 at	
points	of	cell-cell	contact	(Figure	S2A,B).
3.2 | DEPDC1B regulates proliferation and prevents 
precocious differentiation in murine myoblasts
DEPDC1B	function	was	investigated	using	siRNA-mediated	knock-
down in murine satellite cells. Depdc1B	 expression	was	decreased	
by	~72%	by	two	different	Silencer	selected	pre-designed	siRNA	tar-
geting Depdc1b	(N1	and	N2)	compared	to	transfection	with	control	
siRNA	(Figure	1D).	Western	blot	analysis	(Figure	S3A)	confirmed	that	
siRNA	against	Depdc1B	also	reduced	DEPDC1B	at	the	protein	level	
(Figure	S3B).
Satellite	 cells	 knocked	 down	 for	 DEPDC1B	 were	 pulsed	 with	
EdU	for	2	hours	 in	proliferation	medium,	 fixed,	EdU	 incorporation	
visualized,	immunolabelled	for	MYOGENIN	and	counterstained	with	
F IGURE  1 DEPDC1B	controls	proliferation	and	differentiation	in	mouse	satellite	cell-derived	myoblasts.	(A	and	B)	Mouse	satellite	cell-
derived	myoblasts	were	cultured	in	proliferation	medium	(A)	or	switched	to	differentiation	medium	for	2	days	(B),	fixed	and	immunolabelled	
for	DEPDC1B	(HPA072558)	and	β-catenin.	DEPDC1B	was	found	in	the	nuclei	of	both	proliferating	satellite	cell-derived	myoblasts	and	
newly	formed	myotubes	and	unfused	myocytes,	but	not	at	cell-cell-junctions.	(C)	Satellite	cells	were	maintained	in	proliferation	conditions	
or differentiation medium for 1 or 2 days and Depdc1b and Pax7	expression	measured	by	RT-qPCR.	Depdc1b	was	expressed	in	proliferating	
myoblasts,	but	then	decreased	during	differentiation,	mirroring	expression	of	Pax7.	(D)	DEPDC1B	was	effectively	knocked	down	via	siRNA	
transfection	(N1	and	N2)	compared	to	control	siRNA	(Si	control),	as	assessed	by	RT-qPCR.	(E)	Satellite	cells	transfected	with	control	siRNA	
(Si	control)	or	siRNA	against	DEPDC1B	were	maintained	in	proliferation	conditions,	and	either	pulsed	for	EdU	and	immunolabelled	for	
MYOGENIN,	or	(G)	immunolabelled	for	KI67	and	β-tubulin.	(F)	DEPDC1B	knockdown	reduced	proliferation,	but	(H)	promoted	entry	into	
differentiation.	Data	are	mean	±	SEM,	where	an	asterisk	denotes	a	significant	difference	(P	<	.05)	between	control	and	a	test	sample	using	a	
paired	two-tailed	t	test,	with	multiple	fields	examined	from	each	of	3	mice.	Scale	bar	represents	100	µm
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DAPI	 (Figure	 1E).	 Knockdown	of	DEPDC1B	decreased	 the	 rate	 of	
cell	 proliferation	 (EdU	 +	 ve)	 and	 the	 total	 number	 of	 cells	 (DAPI-
stained)	 (Figure	1F)	 compared	 to	 control	 siRNA.	Reduction	of	 cell	
proliferation	following	DEPDC1B	knockdown	was	corroborated	by	a	
decreased	proportion	of	KI67	+	ve	cells	(Figure	1G,H).
Since	proliferation	was	reduced,	we	focused	more	on	the	entry	into	
myogenic	differentiation,	 rather	than	fusion	 index,	which	 is	affected	
by	cell	number.	DEPDC1B	knockdown	caused	an	increased	entry	into	
the	myogenic	differentiation	programme,	as	shown	by	the	higher	pro-
portion	of	myoblasts	with	MYOGENIN	immunolabelling	compared	to	
siRNA	control	(Figure	1E,F).
We	confirmed	that	siRNA-mediated	knockdown	of	DEPDC1B	re-
duced	the	proliferation	rate	by	also	using	a	mix	of	4	siRNAs	targeting	
DEPDC1B	 (Qiagen).	 RT-qPCR	 and	Western	 blot	 analysis	 confirmed	
that	 these	 siRNAs	 also	 reduced	 Depdc1b	 mRNA	 (Figure	 S4A)	 and	
DEPDC1B	at	 the	protein	 level	 (Figure	S3A)	 in	murine	primary	myo-
blasts	compared	to	control	siRNA.	DEPDC1B	knockdown	using	these	
4	separate	siRNAs	also	significantly	reduced	the	proliferation	rate	of	
satellite	cell-derived	myoblasts,	as	shown	by	the	decreased	proportion	
that	had	incorporated	EdU	(Figure	S4B,C).
3.3 | DEPDC1B is required for proliferation in 
human myoblasts
Examining	the	expression	dynamics	of	DEPDC1B during myogenesis 
in	 human	 primary	 myoblasts	 from	 three	 individuals,	 we	 found	 that	
DEPDC1B	 expression	 was	 significantly	 higher	 in	 proliferating	 myo-
blasts	 than	 in	myocytes/myotubes	 at	 differentiation	 days	 1,	 2	 or	 5,	
mirroring cyclin D1	(CD1)	expression,	and	opposite	to	the	expression	
profile of MYOGENIN	(Figure	2A).	A	similar	DEPDC1B	expression	pro-
file	was	found	in	C25Cl48	immortalized	human	myoblasts	in	prolifera-
tion,	compared	to	differentiation	(Figure	2B).	Examination	of	RNA-Seq	
from	 control	 immortalized	 myoblasts	 through	 8	 time	 points	 during	
myogenic differentiation46 also showed that DEPDC1B	expression	fell	
during	differentiation	(Figure	S5A).	Interestingly,	DEPDC1B	expression	
was even lower during differentiation in a myoblast clone containing 
the	D4Z4	contraction	at	chromosome	4q35	that	causes	facioscapulo-
humeral	muscular	dystrophy	1	(OMIM:	158900)	(Figure	S5A).
DEPDC1B	 knockdown	was	 performed	 in	C25Cl48	 human	myo-
blasts	via	transfection	of	a	mix	of	four	siRNAs	(FlexiTube	GeneSolution)	
targeting human DEPDC1B	 mRNA,	with	 high	 knockdown	 efficiency	
compared	 to	 control	 siRNA,	 as	 confirmed	 by	 RT-qPCR	 (Figure	 2C).	
Following	DEPDC1B	 knockdown,	myoblasts	were	 pulsed	with	 EdU,	
which revealed a significantly reduced proliferation rate compared to 
control	siRNA	(Figure	2D).	After	2	days	in	differentiation	medium,	im-
munolabelling	for	MyHC	showed	that	DEPDC1B	knockdown	resulted	
in a higher proportion of differentiated myocytes compared to control 
siRNA	(Figure	2E)	suggesting	that	DEPDC1B	normally	operates	to	in-
hibit myogenic differentiation.
3.4 | DEPDC1A does not affect proliferation in 
mouse or human myoblasts
DEPDC1A	has	functional	redundancy	with	DEPDC1B	in	control	of	
cell cycle progression.1	DEPDC1A	had	a	similar	expression	pattern	
to DEPDC1B	 in	mouse	 satellite	 cell-derived	myoblasts	 (Figure	3A),	
human	 primary	 myoblasts	 (Figure	 3E)	 and	 human	 C25Cl48	 myo-
blasts	 (Figure	3F), with DEPDC1A	expressed	at	significantly	higher	
levels	during	proliferation,	when	compared	to	differentiation.
siRNA-mediated	 knockdown	 efficiency	 for	DEPDC1A was vali-
dated	by	RT-qPCR	 in	both	mouse	 (Figure	3B)	and	human	C25Cl48	
(Figure	3G)	myoblasts.	In	mouse,	DEPDC1A	knockdown	did	not	re-
duce	the	proliferation	rate	as	tested	by	measuring	EdU	incorporation	
(Figure	3C)	or	number	of	myoblasts	(Figure	3C,D),	unlike	knockdown	
of	DEPCD1B.	DEPDC1A	 knockdown	did	 not	 affect	 differentiation	
either,	 as	 assessed	 by	 MYOGENIN	 immunolabelling	 (Figure	 3D).	
Moreover,	 co-knockdown	 of	 both	 DEPDC1A	 and	 DEPDC1B	 to-
gether did not have an additive effect on proliferation rate or differ-
entiation,	 compared	 to	DEPDC1B	knockdown	alone	 (Figure	3C,D).	
Similarly,	 DEPDC1A	 knockdown	 in	 human	C25Cl48	myoblasts	 did	
not	affect	the	proliferation	rate	as	assessed	by	the	proportion	of	EdU	
or	Ki67	+	ve	cells	(Figure	3H).	DEPDC1A	knockdown	in	human	myo-
blasts	though	did	decrease	the	proportion	of	MYOGENIN	+	ve	cells,	
with	more	myoblasts	 (data	not	shown)	and	myocytes	per	unit	area	
(Figure	3I).
3.5 | DEPDC1B affects key regulators of the 
cell cycle
To	characterize	the	effects	of	knocking	down	DEPDC1B	in	proliferat-
ing	human	C25Cl48	myoblasts,	we	analysed	expression	of	many	key	
F IGURE  2 DEPDC1B	controls	proliferation	and	differentiation	in	human	myoblasts.	(A)	cDNA	from	primary	human	myoblasts	obtained	
from	3	individuals	collected	in	proliferation,	and	at	differentiation	day	1,	2	or	3,	was	analysed	for	DEPDC1B,	CD1 and MYOGENIN	expression	
by RT-qPCR. DEPDC1B	was	expressed	at	a	higher	level	in	proliferating	myoblasts	than	during	differentiation,	mirroring	expression	of	
CD1,	but	opposite	to	that	of	MYOGENIN.	(B)	Immortalized	C25Cl48	human	myoblasts	were	maintained	in	proliferation	conditions	or	
differentiation	medium	for	3	or	5	days;	again,	DEPDC1B	was	expressed	at	a	higher	level	in	proliferating	myoblasts	than	differentiation,	
also emulating CD1,	but	contrary	to	the	MYOGENIN,	expression	profile.	(C)	DEPDC1B	knockdown	efficiency	via	siRNA	transfection	was	
effective	compared	to	control	siRNA	(Si	control),	as	quantified	using	RT-qPCR.	(D)	Control	or	DEPDC1B	siRNA-transfected	C25Cl48	human	
myoblasts	were	maintained	in	proliferation	medium,	pulsed	with	EdU	and	immunolabelled	for	β-tubulin.	DEPDC1B	knockdown	decreased	
the	proliferation	rate.	(E)	DEPDC1B	knockdown	C25Cl48	myoblasts	enter	differentiation	earlier,	with	an	increased	proportion	of	MyHC	+	ve	
cells	after	2	days	of	differentiation.	Data	are	mean	±	SEM,	where	an	asterisk	denotes	a	significant	difference	(P	<	.05)	between	control	and	a	
test	sample	using	either	a	paired	(A)	or	an	unpaired	(B-E)	two-tailed	t	test,	with	cDNA	from	3	individuals	or	N	=	3-5	independently	siRNA-
transfected	wells	analysed	per	condition.	Scale	bar	represents	100	µm
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genes	 involved	 in	regulation	of	cell	cycle	progression,	 including	cy-
clins,	cyclin-dependent	kinases	and	cyclin-dependent	kinase	 inhibi-
tors	(Figure	4).	Proliferating	human	myoblasts	were	transfected	with	
siRNA	control	or	siRNA	against	DEPDC1B	and	maintained	in	prolif-
eration	 conditions	 for	 48	 h.	DEPDC1B	 knockdown	was	 confirmed,	
although DEPDC1A	 was	 also	 significantly	 affected	 (Figure	 4A).	
Consistent	with	 reduced	 proliferation,	we	 detected	 an	 increase	 in	
RB1	 expression	 and	 a	 decrease	 in	 E2F1,	CDC6,	ORC1 and CENPF 
(Figure	4B).	Cyclins	A2,	B1,	B2 and E1 were also decreased compared 
to	control	siRNA,	while	cyclins	D1,	D2 and D3	increased	(Figure	4C).	
Cyclin-dependent kinases CDK1,	CDK2 and CDK6 were decreased 
(Figure	4D),	while	 the	cyclin-dependent	kinase	 inhibitors	P15,	P16,	
F IGURE  3 DEPDC1A	does	not	regulate	proliferation	of	myoblasts.	(A)	Murine	satellite	cells	were	maintained	in	proliferation	medium	
or	differentiation	medium	for	12	h,	1	or	2	days,	and	Depdc1a	expression	measured	by	RT-qPCR.	Depdc1a	was	expressed	in	proliferating	
satellite	cell-derived	myoblasts,	but	rapidly	down-regulated	during	differentiation.	(B)	Depdc1a and Depdc1b were effectively knocked down 
individually	or	together	via	siRNA	transfection	compared	to	control	siRNA	(Si	control),	as	shown	by	RT-qPCR.	(C,	D)	SiRNA-transfected	
satellite	cells	were	maintained	in	proliferation	medium,	pulsed	with	EdU	and	immunolabelled	for	MYOGENIN.	(C)	DEPDC1A	knockdown	did	
not	affect	cell	proliferation	or	(D)	differentiation,	while	DEPDC1A/DEPDC1B	co-knockdown	did	not	have	any	additive	effects.	(E)	cDNA	
from	primary	human	myoblasts	obtained	from	3	individuals	collected	in	proliferation,	and	at	differentiation	day	1,	2	or	3,	or	(F)	immortalized	
human	myoblasts	(C25Cl48)	in	proliferation	or	at	differentiation	day	3	or	5	were	analysed	for	DEPDC1A	expression	by	RT-qPCR.	DEPDC1A 
was	expressed	at	significantly	higher	levels	in	proliferating	human	myoblasts	than	during	differentiation.	(G)	DEPDC1A	knockdown	via	
siRNA	transfection	was	efficient,	as	shown	by	RT-qPCR.	(H)	Control	(Si	control)	and	DEPDC1A	siRNA-mediated	knocked	down	proliferating	
human	myoblasts	were	pulsed	with	EdU	and	immunolabelled	for	Ki67.	DEPDC1A	knockdown	did	not	affect	myoblast	proliferation.	(I)	SiRNA-
transfected	human	myoblasts	were	maintained	in	differentiation	medium	for	1	day,	fixed	and	immunolabelled	for	MYOGENIN.	DEPDC1A	
knockdown	inhibited	the	entry	into	myogenic	differentiation,	and	increased	total	cells.	Data	are	mean	±	SEM,	where	an	asterisk	denotes	a	
significant	difference	(P	<	.05)	between	control	and	a	test	sample	using	a	paired	(A-E)	or	unpaired	(F-I)	two-tailed	t	test,	with	multiple	fields	
examined	from	either	N	=	3	mice,	N	=	3	individuals	or	3	or	more	independent	wells.	Scale	bar	represents	100	µm
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P19,	P21,	P27,	P53 and P57 were all significantly increased compared 
to	control	siRNA	(Figure	4E).
3.6 | PITX2 does not control DEPDC1B in 
human myoblasts
DEPDC1B	 is	 repressed	 by	 PITX2,	with	 PITX2	 knockdown	 increas-
ing	DEPDC1B	at	the	protein	 level	 in	mouse	C2C12	myoblasts.6 To 
test	 whether	 this	 regulatory	 mechanism	 is	 conserved	 in	 man,	 we	
first analysed PITX2	 expression.	PITX2	 expression	 in	 immortalized	
human	C25Cl48	myoblasts	increased	during	differentiation	(Figure	
S6A).	As	a	repressor	of	DEPDC1B,	such	an	increase	in	PITX2 could 
explain	 the	 reduction	 of	 DEPDC1B in both human myocytes and 
myotubes	 (Figure	2A,B).	To	 test	 this	hypothesis,	human	 immortal-
ized	 C25Cl48	 myoblasts	 were	 transduced	 with	 retrovirus	 encod-
ing PITX2C,	 and	overexpression	was	validated	by	RT-qPCR	 (Figure	
S6B).	However,	 retroviral-mediated	 overexpression	 of	 PITX2C	 did	
not repress DEPDC1B	expression	 in	proliferating	human	myoblasts	
(Figure	S6B),	and	neither	did	overexpression	of	PITX1	or	PITX3	(data	
not	shown).	We	also	performed	the	complementary	experiment	of	
knocking down PITX2	expression	via	siRNA	and	analysing	DEPDC1B 
expression	after	2	days	of	differentiation	(Figure	S6C).	Knockdown	
efficiency of PITX2	 siRNA	was	validated	 (although	 it	 also	affected	
Pitx1 and Pitx3),	but	no	 increased	DEPDC1B	expression	was	meas-
ured	(Figure	S6C).
3.7 | DEPDC1B functions independently of WNT/β-
catenin signalling in myogenic cells
In	cancer	cells,	DEPDC1B	affects	WNT/β-catenin signalling33 a path-
way also involved in satellite cell regulation.47,48	Therefore,	we	per-
formed	a	double	DEPDC1B/β-catenin	siRNA-mediated	knockdown	
rescue	experiment	in	murine	satellite	cells,	to	test	whether	the	re-
duced proliferation/precocious differentiation observed by knocking 
down	DEPDC1B	alone	could	be	attributed	to	activation	of	β-catenin. 
Efficient	 knockdown	 of	 DEPDC1B	 and/or	 β-catenin compared to 
control	siRNA	was	confirmed	by	RT-qPCR	 (Figure	S7A).	DEPDC1B	
knockdown	again	 reduced	proliferation	 (KI67	+	 ve	myoblasts)	 and	
enhanced	differentiation	 (MYOGENIN	+	ve	myoblasts),	but	knock-
down of β-catenin did not affect either proliferation or differentia-
tion	compared	to	control	siRNA.	Knockdown	of	both	DEPDC1B	and	
β-catenin did not rescue the effects on proliferation or differentia-
tion	compared	to	DEPDC1B	knockdown	alone	(Figure	S7B).
3.8 | Synergistic suppression of proliferation but 
enhancement of differentiation by DEPDC1B and 
RHOA co-knockdown in human myoblasts
DEPDC1B	knockdown	causes	a	proliferation	defect	in	human	HeLa	
cells	by	an	increase	in	RHOA	activation	and	impairment	of	the	de-
adhesion process.1	 PTPRF	 is	 required	 for	 RHOA	 activation,	 and	
F IGURE  4 DEPDC1B	knockdown	
myoblasts	exhibit	deregulation	of	cell	
cycle	genes.	Human	C25Cl48	myoblasts	
were	transfected	with	a	siRNA	control	
(Si	control)	or	a	siRNA	against	DEPDC1B	
(Si	DEPDC1B).	Forty-eight	hours	post-
transfection	in	proliferation	medium,	
RNA	was	extracted	and	expression	of	
cell cycle genes analysed by RT-qPCR. 
(A)	DEPDC1B	knockdown	was	confirmed	
and	compared	to	control	myoblasts.	(B-E)	
Cell cycle inhibitors were up-regulated 
(RB1, P15, P16, P19, P21, P27, P53, P57),	
while genes required for normal cell cycle 
progression	were	down-regulated	(E2F1; 
Cyclins A2, B1, B2, E1; CDk1, CDK2, CDK6). 
Data	are	mean	±	SEM,	where	an	asterisk	
denotes	a	significant	difference	(P	<	.05)	
between control and a test sample using 
an	unpaired	two-tailed	t	test,	with	N	=	3	
independently	siRNA-transfected	wells	
analysed per condition
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DEPDC1B	 inactivates	 RHOA	 by	 competing	 for	 binding	 of	 PTPRF.	
Knockdown	of	RHOA	or	PTPRF	was	able	to	rescue	the	proliferation	
defect	of	DEPDC1B	knockdown	HeLa	cells.1
To	test	this	mechanism	in	human	C25Cl48	myoblasts,	DEPDC1B,	
RHOA	 and	 PTPRF	were	 knocked	 down	via	 siRNA	 transfection	 in-
dividually,	or	 in	combination,	for	48	hours	(Figure	5A).	Knockdown	
of	 RHOA	 reduced	 DEPDC1B	 expression,	 while	 DEPDC1B	 knock-
down	 or	 DEPDC1B/PTPRF	 knockdown	 increased	 RHOA	 expres-
sion	compared	to	control	siRNA	(Figure	5A).	DEPDC1B	knockdown	
induced an increase in RB1,	 MYOD and MYOGENIN compared to 
control	 siRNA, which further supports the observed phenotype of 
suppressed	 proliferation	 and	 augmented	 differentiation.	 RHOA	
knockdown increased MYOD and MYOGENIN compared to control 
siRNA.	 PTPRF	 knockdown	 induced	 a	 moderate	 reduction	 of	 RB1 
and MYOD.	Unexpectedly,	co-knockdown	of	DEPDC1B	and	RHOA	
caused a larger increase in RB1,	MYOD and MYOGENIN	expression	
than	DEPDC1B	knockdown	alone,	so	enhancing,	rather	than	revers-
ing,	the	effect	of	DEPDC1B	knockdown	in	promoting	differentiation	
(Figure	5A).
siRNA-transfected	human	proliferating	C25Cl48	myoblasts	were	
also	pulsed	with	EdU	and	immunolabelled	for	β-tubulin	(Figure	5B)	
or	 for	MyHC	and	DAPI	after	2	days	of	differentiation	 (Figure	5D).	
As	 expected	 from	 Figure	 2,	DEPDC1B	 knockdown	 decreased	 the	
proportion	 of	 human	 myoblasts	 that	 had	 incorporated	 EdU	 com-
pared	 to	 control	 siRNA.	 In	 contrast,	 RHOA	 or	 PTPRF	 knockdown	
did	 not	 affect	 the	 proliferation	 rate.	 However,	 DEPDC1B/RHOA	
or	DEPDC1B/PTPRF	co-knockdown	caused	a	 further	 reduction	 in	
the	proliferation	 rate	 compared	with	DEPDC1B	knockdown	alone	
(Figure	5C).
Again	 as	 expected	 from	 Figure	 2,	 DEPDC1B	 knockdown	 in-
creased	 the	 proportion	 of	 MyHC	 +	 ve	 myocytes	 compared	 to	
control	 siRNA.	 RHOA	 knockdown	 also	 increased	 differentiation,	
while	 PTPRF	 knockdown	 did	 not	 have	 any	 measurable	 effect.	
Simultaneous	 DEPDC1B/RHOA	 knockdown	 caused	 a	 significantly	
more substantial increase in differentiation of human myoblasts 
compared	 to	 knockdown	 of	 either	 DEPDC1B	 or	 RHOA	 alone,	 as	
did	 double	 DEPDC1B/PTPRF	 compared	 to	 knockdown	 of	 either	
DEPDC1B	or	PTRF	alone	(Figure	5E).
3.9 | DEPDC1B knockdown increases myogenic 
differentiation in Rhabdomyosarcoma cells
DEPDC1B	 is	 overexpressed	 in	 many	 cancers,	 where	 it	 promotes	
their	proliferation,	migration	and	invasion.	We	therefore	examined	
DEPDC1B	expression	in	rhabdomyosarcoma	(RMS),38 the most com-
mon soft tissue sarcoma in children and adolescents. There are two 
major	 subtypes	 of	 RMS,	 embryonal	 (ERMS)	 and	 alveolar	 (ARMS).	
We	examined	DEPDC1B	expression	in	rhabdomyosarcoma	tumours	
using	published	RNA-Seq	data	sets	(GSE28511),	profiling	ARMS	and	
ERMS	alongside	control	skeletal	muscle	and	tumour	adjacent	skel-
etal muscle. This analysis revealed that DEPDC1B	was	expressed	at	a	
higher level in rhabdomyosarcoma tumours compared to the skeletal 
muscle	biopsies	(Figure	S5B).
We then measured DEPDC1B and DEPDC1A	 expression	 in	 two	
different	 RMS	 cells	 lines	 in	 proliferating	 conditions,	 Rh30	 (ARMS)	
and	RMS-YM	(ERMS),	and	compared	levels	to	those	in	control	human	
C25Cl48	 myoblasts.	 DEPDC1A and DEPDC1B	 were	 expressed	
at	 a	 higher	 level	 in	 Rh30	 cells,	 compared	 to	 C25CL48	 myoblasts	
(Figure	6A).	Rh30	cells	had	higher	expression	of	PAX3,	MYOD and 
MYOGENIN,	but	less	PAX7 and MYF5,	while	RMS-YM	had	higher	ex-
pression of PAX3, PAX7, MYF5 and MYOGENIN, when compared to 
control	C25CL48	myoblasts	(Figure	6A).
DEPDC1B	 and	 RHOA	 co-knockdown	 synergistically	 inhib-
its proliferation but promotes differentiation in control human 
C25CL48	 myoblasts	 (Figure	 5).	 To	 test	 whether	 DEPDC1B	 and	
RHOA	had	 similar	 effects	 in	ARMS,	Rh30	were	 transfected	with	
control	 siRNA	 and	 siRNA	 against	 DEPDC1B	 and/or	 RHOA	 for	
48	h	in	proliferative	conditions	(Figure	6B).	DEPDC1B	knockdown	
caused an increase in RHOA	expression	in	Rh30	cells. RB1	expres-
sion	 was	 increased	 in	 Rh30	 cells	 knocked	 down	 for	 DEPDC1B,	
but MYOGENIN	 expression	 was	 unchanged	 compared	 to	 control	
siRNA.	 Increased	 MYOGENIN	 expression	 was	 only	 observed	 in	
RHOA	 knocked	 down	 Rh30	 cells.	 Rh30	 cells	 knocked	 down	 for	
both	DEPD1B	and	RHOA	exhibited	no	synergetic	induction	on	RB1 
or MYOGENIN	expression	(Figure	6B).
Next,	 siRNA-transfected	 Rh30	 cells	 were	 maintained	 in	 pro-
liferation	 conditions	 for	 2	 days	 and	 immunolabelled	 for	 KI67	 and	
F IGURE  5 DEPDC1B	and	RHOA	synergize	in	suppressing	proliferation	but	enhancing	differentiation	in	human	myoblasts.	(A)	
Immortalized	human	C25Cl48	myoblasts	were	transfected	with	control	siRNA	(Si	control)	or	siRNA	against	DEPDC1B,	RHOA,	PTPRF,	
DEPDC1B/RHO,	DEPDC1B/PTPRF	or	PTPRF/RHOA.	Transfected	cells	were	maintained	in	proliferation	medium,	mRNA	was	extracted,	and	
expression	of	DEPDC1B,	RHOA,	PTPRF,	RB1,	MYOD and MYOGENIN	was	analysed	by	RT-qPCR.	DEPDC1B	knockdown	cells	had	increased	
RB1,	MYOD and MYOGENIN	expression.	RHOA	knockdown	caused	an	increase	in	MYOD and MYOGENIN.	However,	DEPDC1B/RHOA	double	
knockdown caused a strong additive increase in RB1,	MYOD and MYOGENIN	expression.	(B)	SiRNA-transfected	human	C25Cl48	myoblasts	
were	maintained	in	proliferation,	pulsed	with	EdU,	fixed	and	immunolabelled	for	β-TUBULIN.	(C)	A	reduction	of	the	proliferation	rate	was	
observed	after	DEPDC1B	knockdown,	but	not	with	RHOA	knockdown.	Double	DEPDC1B/RHOA	or	DEPDC1B/PTPRF	knockdown	had	a	
synergistic	effect	in	suppressing	proliferation.	(D)	SiRNA-transfected	human	C25Cl48	myoblasts	were	maintained	in	differentiation	medium	
for	2	days,	fixed	and	immunolabelled	for	MyHC.	Differentiation	was	induced	in	DEPDC1B	knockdown	and	RHOA	knockdown	myoblasts,	
with	an	additive	effect	in	double	DEPDC1B/RHOA	or	DEPDC1B/PTPRF	knockdown	cells.	Data	are	mean	±	SEM,	where	an	asterisk	denotes	
a	significant	difference	(P	<	.05)	between	control	and	a	test	sample,	or	as	indicated	with	a	bar,	using	an	unpaired	two-tailed	t	test,	with	3	
separately	siRNA-transfected	wells	(RT-qPCR)	or	multiple	fields	analysed	from	3	separate	wells	(immunolabelling)	per	condition.	Scale	bar	
equals 100 µm
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MYOGENIN	 (Figure	 6C)	 or	 cultured	 in	 differentiation	 conditions	
for	 5	 days,	 and	 then	 immunolabelled	 for	MyHC	 and	 stained	with	
phalloidin	(Figure	6E).	In	proliferating	conditions,	DEPDC1B	and/or	
RHOA	knockdown	did	not	affect	Rh30	proliferation.	However,	the	
proportion	of	MYOGENIN	+	ve	cells	was	increased	in	RHOA	knock-
down	cells	compared	to	control	siRNA,	but	unaffected	by	DEPDC1B	
knockdown	 (Figure	6D).	After	5	days	 in	differentiation	conditions,	
DEPDC1B	 knockdown	 induced	 a	 slight	 increase	 in	 the	 number	 of	
differentiated	MyHC	+	 ve	 cells	 per	 unit	 area	 compared	 to	 control	
siRNA.	 RHOA	 knockdown	 had	 a	more	 robust	 effect	 in	 promoting	
MyHC	 expression	 in	 Rh30	 cells.	 DEPDC1B/RHOA	 co-knockdown	
trended towards further enhancing the number of differentiated 
MyHC	+	ve	cells	per	unit	area	(P	=	.06),	compared	to	RHOA	knock-
down	alone	(Figure	6F).	As	a	proportion	of	total	Rh30	cells	though,	
those	expressing	MyHC	were	a	minor	component.
4  | DISCUSSION
DEPDC1B	is	a	cell	cycle–regulated	gene	that	is	highly	expressed	dur-
ing	the	G2/M	phase	of	the	cell	cycle.1	DEPDC1B	plays	a	role	in	cell	
cycle	progression	and	is	overexpressed	in	many	cancers.34	Here,	we	
analysed	DEPDC1B	function	during	skeletal	myogenesis.
DEPDC1B	 is	expressed	 in	proliferating	mouse	and	human	myo-
blasts,	 but	 levels	 rapidly	decrease	during	differentiation,	 in	 agree-
ment	with	DEPDC1B	being	almost	undetectable	 in	human	skeletal	
muscle.5	At	the	protein	level,	DEPDC1B	was	present	in	the	nucleus	
in both proliferating murine myoblasts and differentiated multi-
nucleated	myotubes,	 indicating	 that	while	DEPDC1B	 expression	 is	
actively	 repressed	during	differentiation,	 the	protein	could	 remain	
functional	 in	 newly	 formed	 myotubes.	 The	 DEPDC1B	 antibody	
(HPA072558)	recognizes	a	band	of	the	correct	molecular	weight	for	
DEPDC1B	 at	 approximately	 61	 kDa	 on	Western	 blots	 of	 proteins	
from	mouse	myoblasts	 (Figure	S3)	and	 is	 located	 in	 the	nucleus	 in	
various cancer cell lines.37	 However,	 DEPDC1B	 is	 often	 reported	
to also be located at the cell membrane.1,3,6	Interestingly,	when	we	
overexpressed	 a	 V5-tagged	 version	 of	 DEPDC1B	 in	 mouse	 myo-
blasts,	we	found	clear	membrane	localization	(Figure	S2).	In	human	
C25Cl48	myoblasts	though,	we	did	not	observe	nuclear	localization	
with	the	HPA072558	DEPDC1B	antibody,	although	this	antibody	did	
not	recognize	a	band	at	~	61	kDa	on	Western	blots,	instead	recogniz-
ing	a	band	around	42	kDa	(unpublished	data).
To	evaluate	DEPDC1B	function,	we	used	a	knockdown	approach	
via	siRNA	transfection.	DEPDC1B	knockdown	in	mouse	and	human	
myoblasts	 caused	 a	 similar	 phenotype,	 characterized	 by	 a	 robust	
reduction in their proliferation and deregulation of many cell cycle 
genes.	During	 the	G1	 phase,	 RB1	 inactivates	 E2F1	 to	 block	G1/S	
transition.	DEPDC1B	knockdown	myoblasts	had	higher	expression	
of RB1 and a reduction of E2F1 that could potentially cause a block 
in	G1.	DEPDC1B	knockdown	myoblasts	also	exhibited	a	reduction	of	
markers	that	are	normally	increased	during	S	phase	(cyclin A,	CDK1 
and 2)	or	G2	phase	(cyclin B1 and B2).	Finally,	DEPDC1B	knockdown	
cells	had	increased	expression	of	the	CDK	inhibitors	P21,	P27,	P53 
and P57	that	inhibit	cell	cycle	progression	at	different	stages.	Similar	
observations	 have	 been	 made	 in	 other	 cells	 types,	 for	 example	
DEPDC1B	knockdown	also	inhibits	proliferation	in	HeLa1 and human 
malignant melanoma cells.34	In	parallel	with	inhibiting	proliferation,	
DEPDC1B	knockdown	myoblasts	also	undergo	precocious	myogenic	
differentiation.
DEPDC1A	has	a	similar	structure	to	DEPDC1B	and	is	also	regu-
lated	during	the	cell	cycle,	with	DEPDC1A	knockdown	in	HeLa	cells	
causing	a	similar	phenotype	to	DEPDC1B	knockdown,	with	simulta-
neous	depletion	of	both	DEPDC1A	and	DEPDC1B	having	additive	
effects.1 We found that DEPDC1A	has	a	similar	expression	profile	to	
DEPDC1B	in	mouse	and	man,	with	expression	clearly	falling	in	differ-
entiation	compared	to	levels	during	cell	cycle.	However,	DEPDC1A	
knockdown had no effect on murine myoblast proliferation or entry 
into	differentiation	and	did	not	act	 synergistically	with	DEPDC1B.	
It	 is	of	note	that	in	human	myoblasts,	while	DEPDC1A	knockdown	
did	not	affect	EdU	 incorporation	or	Ki67	expression,	 it	did	 lead	to	
an increase in cell number per unit area and fewer cells contain-
ing	MYOGENIN.	 Thus,	 proliferation	 in	 myoblasts	 is	 supported	 by	
DEPDC1B,	with	DEPDC1A	not	appearing	to	have	a	major	role.
To	 investigate	 the	 transcriptional	 regulation	 of	 DEPDC1B,	 we	
examined	 PITX2,	 which	 has	 been	 reported	 to	 be	 a	 repressor	 of	
DEPDC1B	 in	murine	 immortalized	C2	myoblasts.6 To test whether 
this	 regulatory	 mechanism	 was	 conserved	 in	 human	 myoblasts,	
we	 overexpressed	 PITX2C	 or	 knocked	 down	 PITX2,	 but	 neither	
F IGURE  6 DEPDC1B	or	RHOA	knockdown	enhance	myogenic	differentiation	in	Rhabdomyosarcoma	cells.	(A)	Control	human	C25Cl48	
myoblasts	(HCM25),	Rh30	and	RMS-YM	cells	were	maintained	in	proliferation	medium,	mRNA	was	extracted,	and	expression	of	PAX3, 
PAX7, MYF5, MYOD, MYOGENIN, DEPDC1A and DEPDC1B was analysed by RT-qPCR. DEPDC1A or DEPDC1B	were	expressed	at	higher	
levels	in	Rh30	cells	compared	to	control	human	myoblasts.	(B)	Rh30	cells	were	transfected	with	either	control	siRNA	(Si	control)	or	siRNA	
against	DEPDC1B	and/or	RHOA,	mRNA	was	extracted,	and	expression	of	DEPDC1B,	RHOA,	MYOGENIN and RB1 was analysed by RT-qPCR. 
DEPDC1B and/or RHOA	knockdown	were	validated,	and	MYOGENIN	was	only	induced	in	RHOA	knockdown	cells	and	RB1	only	in	DEPDC1B	
knockdown	cells.	No	additive	effects	were	observed	with	DEPDC1B/RHOA	double	knockdown.	(C)	SiRNA-transfected	Rh30	cells	were	
maintained	in	proliferation,	fixed	and	immunolabelled	for	KI67	and	MYOGENIN.	(D)	No	reduction	in	proliferating	cells	was	observed	with	
DEPDC1B	knockdown,	RHOA	knockdown	or	double	DEPDC1B/RHOA	knockdown.	However,	the	number	of	MYOGENIN-positive	cells	
was	increased	only	by	RHOA	knockdown.	(E)	SiRNA-transfected	Rh30	cells	were	maintained	in	differentiation	medium	for	5	days,	fixed	
and	stained	with	Phalloidin	and	immunolabelled	for	MyHC.	(F)	Cell	differentiation	was	slightly	but	significantly	enhanced	by	DEPDC1B	
knockdown,	but	more	robustly	increased	by	RHOA	knockdown,	with	a	trend	(P	=	.06)	towards	an	additive	effect	with	double	DEPDC1B/
RHOA	knockdown	compared	to	RHOA	knockdown	alone.	Data	are	mean	±	SEM,	where	an	asterisk	denotes	a	significant	difference	(P	<	.05)	
between	control	and	a	test	sample,	or	as	indicated	by	a	bar,	using	an	unpaired	two-tailed	t	test,	with	3	separately	siRNA-transfected	wells	
(RT-qPCR)	or	multiple	fields	per	3	wells	(immunolabelling)	per	condition.	Scale	bar	equals	100	µm
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procedure affected DEPDC1B	expression.	Thus,	PITX2	does	not	ap-
pear to have a role in direct transcriptional regulation of DEPDC1B in 
human	myoblasts.	Further	investigations	will	be	required	to	identify	
protein/DNA-binding	 elements	 for	 other	 factors	 involved	 in	myo-
genesis located in DEPDC1B regulatory regions.
To	better	understand	how	DEPDC1B	regulates	myoblast	pro-
liferation,	we	 investigated	pathways	described	 in	other	 systems.	
DEPDC1B	 is	 overexpressed	 in	 non-small-cell	 lung	 carcinoma,	
where	 it	can	enhance	both	cell	migration	and	 invasion,	an	effect	
partially	 due	 to	 activation	 of	 canonical	WNT	 signalling	 through	
β-catenin.33	In	mouse,	while	Wnt/β-catenin signalling is transiently 
active	 in	myoblasts	 during	muscle	 regeneration	 in	 adult,	 genetic	
inactivation of β-catenin in satellite cells does not affect regener-
ation.49	 Interestingly	though,	constitutive	activation	of	β-catenin 
in	 satellite	 cells	 extends	 the	 myoblast	 phase	 of	 regeneration	 to	
ultimately generate smaller fibres and increase muscle fibrosis.49 
We	previously	reported	that	inhibiting	Axin1/2	in	satellite	cells	in-
creases signalling via β-catenin to cause inhibited proliferation and 
precocious entry into differentiation.47	 Thus,	 DEPDC1B	 knock-
down caused a phenotype similar to activation of β-catenin.47 We 
therefore	tried	to	rescue	DEPDC1B	knockdown	by	also	down-reg-
ulating β-catenin,	but	DEPDC1B/β-catenin double knockdown did 
not	rescue	proliferation	or	precocious	differentiation.	Therefore,	
DEPDC1B	function	is	not	directly	associated	with	β-catenin levels 
in skeletal myogenesis.
DEPDC1B	 plays	 a	 role	 in	 control	 of	 cell	 cycle	 progression	 in	
some	cells	via	a	repressive	effect	on	the	small	RHO	GTPase	RHOA.1 
DEPDC1B	inactivates	RHOA	by	competing	for	binding	of	PTPRF.	In	
the	absence	of	DEPDC1B,	RHOA	activation	 is	maintained	and	cell	
cycle progression inhibited. To determine whether a potential over-
activation	of	RHOA	was	responsible	for	the	proliferation	defect	ob-
served	 in	DEPDC1B	knocked	down	human	myoblasts,	we	reduced	
levels	of	DEPDC1B	and/or	RHOA	via	siRNA.	Contrary	to	HeLa	cells,	
RHOA	 reduction	 in	 DEPDC1B	 knockdown	 human	 myoblasts	 was	
unable	 to	 rescue	 proliferation.	 Surprisingly	 though,	 simultaneous	
down-regulation	of	DEPDC1B	and	RHOA	actually	acted	synergisti-
cally	to	further	reduce	cell	proliferation	and	induce	differentiation,	
with a synergistic increase in RB1,	MYOD and MYOGENIN	 expres-
sion.	DEPDC1B	plays	a	key	role	in	the	maintenance	of	cell	prolifera-
tion,	and	complementarily,	RHOA	inhibits	myogenic	differentiation.	
Knocking down both genes therefore allows a synergetic induction 
of	differentiation,	with	withdrawal	from	cell	cycle	being	a	prerequi-
site for myogenic differentiation.
RHOA	 promotes	 myogenic	 differentiation	 but	 needs	 to	 be	
down-regulated to then allow fusion.8,11,13,15-17 In human myo-
blasts,	we	found	that	RHOA	knockdown	does	not	affect	prolifer-
ation,	but	 causes	precocious	entry	 to	differentiation,	 suggesting	
an	inhibitory	effect	of	RHOA	on	induction	of	myogenic	differenti-
ation.	The	active	form	of	RHOA	is	high	in	proliferation	and	at	the	
later	stages	of	differentiation,	but	not	at	the	initiation	of	differen-
tiation,50	 supporting	 a	 potential	 inhibitory	 role	 of	 RHOA	on	 dif-
ferentiation.	However,	 in	 proliferating	murine	C2C12	myoblasts,	
overexpression	 of	 a	 dominant-negative	 RHOA	 (N19-RhoA)11 or 
RHO-specific	 inhibitor	 (tat-C3)17 inhibits myogenic differentia-
tion. These contradictory results could be due to cell line differ-
ences	 (immortalized	 murine	 C2C12	 versus	 immortalized	 human	
myoblasts)	 or	 in	 the	 strategy	 to	 either	 inactivate	 RHOA	 or	 re-
duce	its	levels	via	siRNA.	A	specific	level	and	temporal	activation	
of	 RHOA	 seem	 to	 be	 important	 to	 allow	 coordinated	 myogenic	
progression.17
DEPDC1B	is	overexpressed	in	many	cancers,3,35,36 and we found 
higher	 expression	 of	DEPDC1B in human rhabdomyosarcoma com-
pared	to	skeletal	muscle,	and	in	Rh30	(ARMS)	cells	compared	to	human	
C25Cl48	myoblasts.	Knockdown	of	DEPDC1B	in	Rh30	cells	increased	
expression	of	RB1, but not MYOGENIN.	However,	DEPDC1B	knock-
down	did	not	otherwise	affect	proliferation	(proportion	of	cells	with	
KI67)	or	entry	into	myogenic	differentiation	(proportion	of	cells	with	
MYOGENIN).	However,	after	5	days	in	differentiation	conditions,	the	
number	of	 cells	with	 the	 sarcomeric	protein	MyHC	was	moderately	
increased	by	DEPDC1B	knockdown.	RHOA	knockdown	alone	in	Rh30	
triggered an increase in MYOGENIN	expression	and	a	higher	number	
of	cells	with	MYOGENIN	and	MyHC.	This	still	represented	only	a	small	
proportion	 of	 total	 cells,	 but	MyHC	 containing	 Rh30	 cells	 had	 pre-
sumably	exited	cell	cycle.	While	we	found	that	siRNA	against	RHOA	
did	not	affect	Rh30	proliferation,	dominant-negative	RHOAN19	has	
been	reported	to	reduce	rhabdosphere	formation	in	multiple	RMS	cell	
lines.51	 A	 constitutively	 active	 RHOA	 (RHOAV14),	 however,	 blocks	
myogenic	 differentiation	 (MCad, MyoD, MyoG	 expression)	 to	 retain	
ERMS	cells	in	a	more	undifferentiated	and	self-renewing	state.51	Thus,	
in	 human	 myoblasts	 and	 Rh30	 cells,	 RHOA	 knockdown	 promotes	
myogenic	differentiation,	supporting	a	role	for	RHOA	as	an	inhibitor	
of precocious differentiation.
There	are	other	pathways	that	DEPDC1B	may	also	interact	with.	
RAC1	is	regulated	by	DEPDC1B	in	some	cell	lines5,6 and in muscle 
cells,	and	RAC1	inhibits	myogenic	differentiation	and	induces	loss	
of	cell	contact	inhibition.	Moreover,	RAC1	is	activated	in	rhabdo-
myosarcoma	cell	 lines,	 and	overexpression	of	dominant-negative	
forms	inhibits	cell	proliferation	of	RMS.22	Therefore,	a	potential	in-
teraction	of	DEPDC1B	and	RAC1	could	occur	in	muscle.	DEPDC1B	
overexpression	also	increases	phosphorylation	of	ERK,3,5 and the 
MEK/ERK	pathway	controls	myoblast	proliferation,	while	MEK	in-
hibition	in	RAS-mutated	rhabdomyosarcoma	can	induce	myogenic	
differentiation.	Finally,	N-cadherin	acts	to	maintain	satellite	cells	
in quiescence.52	 N-cadherin-dependent	 intercellular	 adhesion	
also	has	a	major	role	in	cell	cycle	exit	and	in	induction	of	the	mus-
cle	differentiation	programme	via	a	positive	 regulation	of	RHOA	
and	a	negative	 regulation	of	RAC1,	CDC42	and	JNK	activities.53 
N-cadherin	knockdown	in	C2	myoblasts	causes	an	increase	in	cell	
proliferation	and	a	defect	of	differentiation	characterized	by	a	de-
crease in p21,	p27 and MYOGENIN.	DEPDC1B	knockdown	has	an	
opposite	phenotype,	with	a	defect	of	proliferation	and	an	 induc-
tion of differentiation with an increase in p21,	p27 and Myogenin. 
This	could	 suggest	a	potential	 repressive	effect	of	DEPDC1B	on	
N-cadherin.
In	 summary,	DEPDC1B	 is	 expressed	 in	 proliferating	 myoblasts	
where	 it	 is	 localized	to	 the	nucleus	 in	mouse.	DEPDC1B	functions	
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in mouse and man to maintain myoblast proliferation and inhibit 
precocious entry into myogenic differentiation during adult skeletal 
myogenesis.
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